DiaMedica Therapeutics (DMAC) Change in Acquisitions & Divestments (2019 - 2026)

DiaMedica Therapeutics' Change in Acquisitions & Divestments history runs 8 years deep, the most recent figure standing at $16.8 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 24.37% year-over-year to $16.8 million in Q1 2026; TTM through Mar 2026 was $60.4 million, a 3.28% increase from a year earlier, with the FY2025 full-year figure at $57.1 million, down 3.18% from the prior year.
• Change in Acquisitions & Divestments improved to $16.8 million in Q1 2026 per DMAC's latest filing, from $16.1 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $18.5 million in Q2 2025 and bottomed at $9.1 million in Q3 2025.
• The 5-year median for Change in Acquisitions & Divestments is $14.5 million (2022), against an average of $14.2 million.
• Across the five-year window, Change in Acquisitions & Divestments soared 45.45% in 2024 and tumbled 43.1% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $14.5 million in 2022, then retreated by 24.37% to $11.0 million in 2023, then surged by 45.45% to $16.0 million in 2024, then climbed by 0.34% to $16.1 million in 2025, then climbed by 4.58% to $16.8 million in 2026.
• Per Business Quant, the three latest DMAC Change in Acquisitions & Divestments figures stand at $16.8 million (Q1 2026), $16.1 million (Q4 2025), and $9.1 million (Q3 2025).